首页> 外文OA文献 >Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I–III Non-small Cell Lung Cancer Patients
【2h】

Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I–III Non-small Cell Lung Cancer Patients

机译:肺静脉循环肿瘤细胞分子亚型预测I-III期非小细胞肺癌患者的预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Background: There was rare studies on prognosis of pulmonary venous CTC and early or advanced NSCLC patients. We want to investigate whether CTCs and the subtype of it can predict the prognosis of NSCLC patients.Patients and Methods: One hundred and fourteen patients with stage I-III NSCLC were included CanPatrol™ CTC analysis. PD-L1 expression level were detected in CTC of pulmonary vein. PD-L1, number of CTC in pulmonary, CTC's subtype, clinical characteristics, prognosis of patients were analyzed.Results: 110/114 (96.5%) patients could be found CTCs in pulmonary vein, 58/114 (50.9%) patients had CTC≥15/ml in pulmonary vein, 53/110 patients (48.2%) were defined as having MCTC subtype and 56/110 patient were found have PD-L1 (+) CTC in pulmonary vein. Multivariate analyses showed that PVCTC, MCTC, and stage were independent factors of DFS (P < 0.05). No OS difference was found between number of CTC (P = 0.33) and other CTC factors (P > 0.05), only stage was independent factor of OS (P = 0.019). There were decreases of CTC number and MCTC number in EGFR mutant subgroup (P = 0.0009 and P = 0.007). There were increases of CTC (P = 0.0217), MCTC (P = 0.0041), and PD-L1 (+) CTC (P = 0.0002) number in KRAS mutant subgroup. There was increase of MCTC (P =0.0323) number in BRAF mutant. There were fewer CTCs in pulmonary vein for patients with EGFR mutant than in patients with full wild-type gene (P = 0.0346). There were more PD-L1 positive CTCs in pulmonary vein for patients with ALK rearrangement, KRAS mutant, BRAF mutant, or ROS1 mutant than in patients with full wild-type gene (P = 0.0610, P = 0.0003, P = 0.032, and P = 0.0237). There were more mesenchymal CTCs in pulmonary vein for patients with KRAS mutant and BRAF mutant than in patients with full wild-type gene (P = 0.073 and P = 0.0381). There were fewer mesenchymal CTCs in pulmonary vein for patients with EGFR mutant than in patients with full wild-type gene (P = 0.0898).Conclusions: The patients with high number of CTCs, MCTCs, or PD-L1 (+) CTCs in pulmonary vein experienced poor prognosis of DFS. There are obvious correlations between the CTC subtype of NSCLC and the gene subgroups of tumor tissue.
机译:背景:有肺静脉CTC和早期的预后罕见研究或晚期NSCLC患者。我们要调查的CTC和它的亚型是否能预测NSCLC patients.Patients和方法的预测:114个例I-III期NSCLC患者纳入CanPatrol™CTC分析阶段。 PD-L1表达水平在肺静脉的CTC进行检测。 PD-L1,CTC在肺,CTC的亚型,临床特征的数量,患者的预后。结果:110/114肺静脉(96.5%)患者可以发现的CTC,58/114(50.9%)患者CTC ≥15/ ml,在肺静脉,53/110例(48.2%)被定义为具有MCTC亚型并发现56/110患者具有PD-L1(+)CTC在肺静脉。多变量分析表明,PVCTC,MCTC和分期是DFS的独立因素(P <0.05)。没有OS差异CTC的其他CTC因子(P> 0.05)数(P = 0.33)之间发现,仅阶段是OS的独立因素(P = 0.019)。有在EGFR突变亚组(P = 0.0009和P = 0.007)的CTC数和MCTC数量减少。有CTC(P = 0.0217),MCTC(P = 0.0041)的增加,和PD-L1(+)CTC(P = 0.0002)在KRAS突变亚组数。有的MCTC(P = 0.0323)号在BRAF增加突变体。有在肺静脉更少的CTC患者的EGFR的患者比全野生型基因(P = 0.0346)突变体。有更多的PD-L1阳性的CTC在患者肺静脉与ALK重排,KRAS突变体,BRAF突变体,或ROS1突变体的患者比全野生型基因(P = 0.0610,P = 0.0003,P = 0.032和P = 0.0237)。有在肺静脉更多的间充质的CTC患者KRAS突变和BRAF的患者比全野生型基因(P = 0.073和P = 0.0381)突变体。有在肺静脉更少的间充质的CTC患者的EGFR的患者比全野生型基因(P = 0.0898)的突变体。结论:在肺高数目的CTC,MCTCs,或PD-L1(+)的CTC的患者静脉经历DFS的预后较差。有NSCLC的CTC亚型和肿瘤组织的基因子群之间明显的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号